Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Seres Therapeutics ( (MCRB) ).
Seres Therapeutics faces a Nasdaq compliance challenge as its stock fell below the $1 bid price requirement, prompting a 180-day period to rectify the situation or face potential delisting. Meanwhile, the company reported promising results from its SER-155 trial, showing a significant reduction in bloodstream infections among patients, which could lead to breakthrough therapy designation. Financially, Seres completed the sale of its VOWST business, bolstering funding for operations into late 2025, while actively seeking a strategic partnership to expand SER-155’s market reach.
Learn more about MCRB stock on TipRanks’ Stock Analysis page.